Aptevo to present multispecific CD40 platform at SITC annual meeting

Aptevo will present its multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting on Nov. 4-8, 2026. The meeting is scheduled for the Phoenix Convention Center in Phoenix, Arizona. The presentation will cover tumor-directed CD40-activating multispecific molecules aimed at boosting anti-tumor immunity in solid tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202610140846ACCESSWRNAPR_____1236659) on October 14, 2026, and is solely responsible for the information contained therein. (C)